Opthea Ltd (FRA:UKJ)

€ 0.408 -0.008 (-1.92%) Market Cap: 525.70 Mil Enterprise Value: 496.53 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 29/100

Opthea Ltd Key Opinion Leader Event On Sozinibercept In Wet Age Related Macular Degeneration Presentation Transcript
Apr 02, 2024
Opthea Ltd at Jefferies Healthcare Conference Transcript
Jun 07, 2023
Opthea Ltd at Oppenheimer Healthcare Conference (Virtual) Transcript
Mar 13, 2023
Opthea Ltd at SVB Securities Global Biopharma Conference (Virtual) Transcript
Feb 15, 2023
Opthea Ltd at SRAX Sequire Biotechnology Conference (Virtual) Transcript
Feb 02, 2023
Opthea Ltd at Jefferies London Healthcare Conference Transcript
Nov 15, 2022
Opthea Ltd at H C Wainwright Ophthalmology Virtual Conference Transcript
Aug 17, 2022
Opthea Ltd at H C Wainwright Global Investment Conference (Virtual) Transcript
May 24, 2022
Opthea Ltd at ASX Small and Mid-Cap Conference (Virtual) Transcript
Mar 16, 2022

Opthea Ltd at ASX Small and Mid-Cap Conference (Virtual) Transcript

Mar 16, 2022 / NTS GMT

Release Date Price: €0.488562 (+1.92%)

Transcript

Megan Baldwin

Opthea Limited - CEO & MD

Thanks very much for the opportunity to present at this conference. It's a pleasure to be here. And thanks, everyone, for tuning in.

We are a retinal eye disease company. We're developing a novel therapy for the treatment of the leading cause of blindness in the elderly population, which is wet age-related macular degeneration. And it's a pleasure to be able to tell you a little bit about our development program, which is right now in the last and final stage of clinical development, which is Phase 3 clinical trials for the treatment of wet AMD.

This is the requisite disclaimer regarding forward-looking statements. So let me tell you a little bit of a snapshot, a little bit about OPT-302, which is our lead clinical development candidate for the treatment of wet AMD. This molecule is a first-in-class VEGF-C/D trap inhibitor. It's essentially a therapy for the treatment of wet AMD that is to be used in combination with the current approved standard of care treatments for this disease, in order to produce better visual acuity outcomes for patients

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.